CClinicalTrials.gg
Sign In
RecruitingNCT07167160Updated Dec 18, 2025

Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

A Phase 2 interventional study of Camrelizumab combined with chemotherapy in Cervical Cancer and Immunochemotherapy, sponsored by Women's Hospital School Of Medicine Zhejiang University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Women's Hospital School Of Medicine Zhejiang University · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Mar 2025, registered Sep 2025).
  • Started Mar 2025; still recruiting 1 year 6 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Female
01

Study summary

Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.

02

Conditions studied

  • Cervical Cancer
  • Immunochemotherapy
03

In context

Uterine Cervical Neoplasms

1,881 studies on the registry are indexed under Uterine Cervical Neoplasms; 567 are open to participants now.

This study's planned enrollment of 59 is below the median of 100 across 1,377 interventional studies indexed under Uterine Cervical Neoplasms.

Browse Uterine Cervical Neoplasms studies →

Lead sponsor

Women's Hospital School Of Medicine Zhejiang University is the lead sponsor of 74 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;
  2. Positive PD-L1 expression;
  3. ECOG score ≤1

Exclusion criteria

Exclusion Criteria:

  1. Positive parametrium or surgical margin;
  2. Incomplete radical surgery;
  3. Residual target lesions;
  4. Active autoimmune disease or autoimmune disease requiring systemic treatment;
  5. Previous treatment with immune checkpoint inhibitors.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (estimated)

Study arms

  • Experimental
    chemotherapy group

    Drug: Camrelizumab combined with chemotherapy

Interventions

  • DrugCamrelizumab combined with chemotherapy

    Camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery

06

What researchers measure

Primary outcomes

  1. 3-year disease-free survival rate

    Time frame: from enrollment until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 100 months

07

Study locations

1 of 1 sites recruiting
  • Women's Hospital, School of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310000, China
    Recruiting
08

References and documents

Publications

  • Chen L, Chen T, Tu N, Dong L, Zhang Y, Wang H, Shen Y. Camrelizumab combined with chemotherapy as postoperative adjuvant therapy after radical surgery for cervical cancer patients with pathologically positive lymph nodes: a prospective multicenter phase II clinical trial. J Gynecol Oncol. 2026 Jul 9. doi: 10.3802/jgo.2027.38.e1. Online ahead of print. PubMed 42471761 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07167160
Lead sponsor
Women's Hospital School Of Medicine Zhejiang University
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
Mar 10, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Dec 18, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Uterine Cervical Neoplasms→

Other studies from this sponsor

Women's Hospital School Of Medicine Zhejiang University

Start the discussion